Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Longterm Results From the Phase 3 SUNRISE-2 Study

被引：0
|
作者：
Yardley, Jane [1 ]
Karppa, Mikko [2 ,3 ]
Inoue, Yuichi [4 ]
Pinner, Kate [1 ]
Perdomo, Carlos [5 ]
Filippov, Gleb [5 ]
Kubota, Naoki [6 ]
Moline, Margaret [5 ]
机构：
[1] Eisai Ltd, Bunkyo City, Japan
[2] Oulu Univ Hosp, Oulu, Finland
[3] Univ Oulu, Oulu, Finland
[4] Tokyo Med Univ, Tokyo, Japan
[5] Eisai Inc, Bunkyo City, Japan
[6] Eisai & Co Ltd, Bunkyo City, Japan
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
420
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial (vol 2, e1918254, 2019)
    Rosenberg, Russell
    Murphy, Patricia
    Zammit, Gary
    [J]. JAMA NETWORK OPEN, 2021, 4 (08)
  • [22] Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials
    Huang, Zhaoyang
    Zhan, Shuqin
    Chen, Chunyan
    Zhang, Ruoxi
    Zhou, Yanling
    He, Jingjing
    Lin, Zhaocun
    Bao, Cungang
    Zhu, Shuangpeng
    Zhao, Jianjun
    Zhang, Shengan
    Jiang, Yu
    Wang, Yuping
    [J]. SLEEP, 2024, 47 (02)
  • [23] Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer’s Disease Dementia: Results From a Phase 2 Randomized Clinical Trial
    Margaret Moline
    S. Thein
    M. Bsharat
    N. Rabbee
    M. Kemethofer-Waliczky
    G. Filippov
    N. Kubota
    S. Dhadda
    [J]. The Journal of Prevention of Alzheimer's Disease, 2021, 8 : 7 - 18
  • [24] Key results from two phase 3 clinical trials on the efficacy and safety of daridorexant in patients with chronic insomnia disorder: a plain language summary
    Mignot, Emmanuel
    Mayleben, David
    Fietze, Ingo
    Leger, Damien
    Zammit, Gary
    Bassetti, Claudio L.
    Kinter, Dalma Seboek
    Roth, Thomas
    [J]. FUTURE NEUROLOGY, 2023, 18 (02) : 245 - 253
  • [25] Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial
    Moline, Margaret
    Thein, S.
    Bsharat, M.
    Rabbee, N.
    Kemethofer-Waliczky, M.
    Filippov, G.
    Kubota, N.
    Dhadda, S.
    [J]. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2021, 8 (01): : 7 - 18
  • [26] Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
    Menzies-Gow, Andrew
    Corren, Jonathan
    Bourdin, Arnaud
    Chupp, Geoffrey
    Israel, Elliot
    Griffiths, Janet
    Hellqvist, Asa
    Bowen, Karin
    Kaur, Primal
    Almqvist, Gun
    Ponnarambil, Sandhia
    Colice, Gene
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB249 - AB249
  • [27] Efficacy and Safety of Abatacept Over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study
    Furie, Richard
    Nicholls, Kathy
    Cheng, Tien-Tsai
    Houssiau, Frederic
    Burgos-Vargas, Ruben
    Chen, Shun-Le
    Aranda, Richard
    Meadows-Shropshire, Stephanie
    Kinaszczuk, Michael
    Merrill, Joan T.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S962 - S963
  • [28] Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study
    Kiani, S.
    Jacobs, J. S.
    Deasi, B.
    Aggarwal, K.
    Murray, S. C.
    Iocca, H.
    Lumry, W. R.
    [J]. ALLERGY, 2021, 76 : 16 - 16
  • [29] Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study
    Cutler, Andrew
    Aaronson, Scott T.
    Mattingly, Gregory W.
    Wilkinson, Samuel T.
    Lasser, Robert
    Nandy, Indrani
    Werneburg, Brian
    Jonas, Jeffrey
    Kanes, Stephen J.
    Mariano, Timothy
    [J]. BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S161 - S161
  • [30] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
    Mignot, Emmanuel
    Mayleben, David
    Fietze, Ingo
    Leger, Damien
    Zammit, Gary
    Bassetti, Claudio L. A.
    Pain, Scott
    Kinter, Dalma Seboek
    Roth, Thomas
    [J]. LANCET NEUROLOGY, 2022, 21 (02): : 125 - 139
12345